Related Experiment Video

Updated: Jun 26, 2026

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

Colchicine in Coronary Artery Disease-Too Much of a Good Thing?

Hui Zhen Lo1, Sanjay Patel2,3, Jamie Layland4,5

  • 1Bayside Health (Peninsula), Frankston, VIC 3199, Australia.

Journal of Cardiovascular Development and Disease
|June 25, 2026
PubMed

Insights

Colchicine shows potential as an affordable addition to standard care for coronary artery disease (CAD). However, recent evidence suggests it may not be as effective for secondary prevention in CAD as once believed.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Coronary artery disease (CAD) remains a leading global cause of death.
  • Inflammation is increasingly recognized as a therapeutic target for cardiovascular event reduction, complementing traditional lipid-lowering strategies.

Purpose of the Study:

  • To review current evidence on colchicine's efficacy in CAD secondary prevention.
  • To synthesize findings from recent trials and meta-analyses to clarify colchicine's role.

Main Methods:

  • Review of recent clinical trials (LoDoCo2, COLCOT, etc.) and meta-analyses.
  • Analysis of data regarding colchicine's impact on cardiovascular events in CAD patients.

Main Results:

  • Colchicine is a low-cost, widely available medication.
  • Evidence suggests colchicine's effectiveness in secondary CAD prevention may be less than previously anticipated.
  • Further research is needed to define its precise role and patient selection.

Conclusions:

  • Colchicine presents a potential, affordable adjunct to lipid-lowering therapy for CAD.
  • Its role in secondary prevention warrants careful consideration due to emerging evidence.
  • Ongoing studies are crucial for understanding colchicine's benefits versus risks in diverse populations.

Keywords:
colchicinecoronary artery disease

More Related Videos

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...